‘Decide within 3 months': Delhi HC tells CDSCO on plea against use of diabetes drugs in weight management
A bench of Chief Justice Devendra Upadhyaya and Justice Tushar Rao Gedela was hearing a public interest litigation (PIL) against the manner in which Glucagon Like Peptide -1 Receptor Agonist (RA) (GLP-1-RA) drugs, specifically semaglutide, tirzepatide, and liraglutide have been granted marketing approval in India for weight loss and aesthetic purposes, despite being originally approved for treatment of Type 2 diabetes.
The PIL, filed through advocate Rohit Kumar, referred to the significant risks posed by these medications, including pancreatitis, gastrointestinal damage, thyroid and pancreatic cancers, cardiovascular complications, metabolic dysregulation, and optic neuropathy.
In its order, the CJ Upadhyaya-led Bench directed the PIL litigant to submit to CDSCO the scientific studies and data relied upon in the petition.
Asking the CDSCO to decide the representation within 3 months, the Delhi High Court closed the proceedings and disposed of the matter.
As per the petition, GLP-1-RA drugs were originally developed and internationally approved for the treatment of Type 2 Diabetes Mellitus, but over the past few years, have been "repurposed and approved often through accelerated pathways for obesity treatment and chronic weight management, based largely on short-term efficacy trials".
Questioning the CDSCO's grant of marketing approval of these drugs for weight loss purposes in the country, the plea cited limited safety data, lack of India-specific clinical trials, and absence of a robust pharmacovigilance or regulatory oversight mechanism.
It said that there is no evidence to suggest that these drugs have undergone rigorous safety evaluation within the Indian population and highlighted the "aggressive" and "unregulated marketing" of these drugs for aesthetic and non-medical purposes.
"Pharmaceutical companies, clinics, and digital wellness platforms are promoting semaglutide and tirzepatide as 'quick-fix' weight loss solutions, especially targeting younger populations, including teenagers. The increasing normalisation of these drugs in aesthetic medicine is alarming," added the PIL.
Further, it said that the lack of transparency surrounding the clinical data submitted for approval of these drugs, the absence of publicly available safety profiles, and the regulatory silence on their off-label use violated the right to health, which encompasses the right to safe medication, informed decision-making, and access to scientific information.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
13 hours ago
- Time of India
5 heart-healthy foods to add to your diet
Cardiovascular diseases claim millions of lives annually, highlighting the importance of heart health. Incorporating leafy greens rich in Vitamin K, whole grains high in fiber, and berries abundant in flavonoids can significantly improve cardiovascular function. Avocados, packed with monounsaturated fats, and fatty fish containing omega-3 acids also contribute to a healthier heart. About 17.9 million die each year due to cardiovascular diseases (CVDs) every year. CVDs are the leading cause of death globally, according to the WHO. Maintaining heart health is crucial, and diet plays a pivotal role in it. Here is a list of foods that can improve your heart health. Leafy greens Eat your greens. Yes, that's right. Leafy greens such as spinach, kale, and Swiss chard are nutritional powerhouses. They are an excellent source of vitamin K, which helps protect arteries and promote proper blood clotting. A recent study from Edith Cowan University (ECU), the University of Western Australia, and the Danish Cancer Institute has shown that a cup and a half of leafy green vegetables could go a long way to addressing atherosclerotic vascular diseases (ASVD's). The study found that higher dietary intake of Vitamin K1 can reduce the risk of ASVD. 'Leafy green and cruciferous vegetables, like spinach, kale, and broccoli, contain Vitamin K,1 which may assist in preventing vascular calcification processes that characterise cardiovascular disease. The great news is that these vegetables can be easily incorporated into your daily meals,' the lead researcher said. Whole grains Refined grains are your heart's biggest enemy. Instead, switch to whole grains, such as oats, quinoa, brown rice, and whole wheat. They are high in fiber, which helps reduce cholesterol and maintain healthy blood sugar levels. A 2021 study showed that eating more refined grains increases the risk of major cardiovascular disease, such as heart attack, stroke, and even death. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Here's The Estimated Cost of a 1-day Gutter Guards Installation HomeBuddy Click Here Undo Whole grains, on the other hand, are linked to a lower risk of heart disease. Berries Who knew eating something as sumptuous as berries could actually boost your heart health! These include blueberries, strawberries, and raspberries. They contain flavonoids, which can lower blood pressure and reduce oxidative stress. A 2019 study by researchers at the University of East Anglia found that eating a cup of blueberries a day reduces risk factors for cardiovascular disease. "Previous studies have indicated that people who regularly eat blueberries have a reduced risk of developing conditions, including type 2 diabetes and cardiovascular disease. This may be because blueberries are high in naturally occurring compounds called anthocyanins, which are the flavonoids responsible for the red and blue colour in fruits. We found that eating one cup of blueberries per day resulted in sustained improvements in vascular function and arterial stiffness - making enough of a difference to reduce the risk of cardiovascular disease by between 12 and 15 per cent," the researchers of the study said. Avocados Yes, the creamy green fruit can not only bless your taste buds, but also boost your heart health. They are rich in monounsaturated fats, which can help lower 'bad' LDL cholesterol and increase 'good' HDL cholesterol. A 2022 study published in the Journal of the American Heart Association found that eating two or more servings of avocado weekly was associated with a lower risk of cardiovascular disease. The participants in the study, who ate at least two servings of avocado each week, had a 16% lower risk of cardiovascular disease and a 21% lower risk of coronary heart disease, compared to those who never or rarely ate avocado. Diet to reduce body inflammation: Foods that help reduce inflammation. Fatty fish Another way to enhance your heart health is to add more fatty fish to your diet. Fatty fish, such as salmon, mackerel, sardines, and trout, are rich in omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which have been shown to reduce inflammation and improve overall heart health. A 2023 study by researchers from Karolinska Institute found that the risk of CVDs can be reduced by eating more fatty fish. People with close relatives who have suffered from cardiovascular disease may also benefit from eating more oily fish.
The Print
17 hours ago
- The Print
Health Ministry launches SHRESTH index to strengthen state drug regulatory systems
The initiative, proposed by the Central Drugs Standard Control Organisation (CDSCO), aims to improve the performance of state drug regulatory authorities, ensuring that drug safety and quality standards are consistently met, the ministry said in a statement. The index was launched on Tuesday by Union Health Secretary Punya Salila Srivastava virtually in the presence of Drug Controller General of India Dr Rajeev Singh Raghuvanshi. New Delhi, Aug 13 (PTI) The Union Health Ministry has launched the State Health Regulatory Excellence Index, a first-of-its-kind national initiative to benchmark and strengthen state drug regulatory systems through a transparent and data-driven framework. In a meeting attended virtually by the health secretaries, principal health secretaries and the drugs controllers from states and Union Territories, Srivastava reiterated that the health of all citizens begins with the safety, quality, and efficacy of the medicines they consume. Ensuring their quality is the government's commitment, she said. 'Our federal structure is designed to regulate a complex and globally significant pharmaceutical industry. The only way forward is cooperative action to ensure medicines made in India are trusted everywhere, starting with every citizen in India,' the Union health secretary said. Srivastava highlighted the crucial role played by states and Union Territories in ensuring quality manufacturing and distribution in India and the need for recognising and supporting their best practices and growth. 'States have strong regulatory certification. State Health Regulatory Excellence Index (SHRESTH) is a virtual gap assessment tool for states to assess their current position and help towards maturity certification,' she added. Highlighting India's achievement of WHO ML3 status for vaccines, Srivastava stressed the next step is to elevate medicines to the same global standard, advancing international harmonisation and reinforcing India's role as the 'pharmacy of the world'. Several upcoming initiatives were also outlined, including the extension of the Not of Standard Quality (NSQ) dashboard to all states, the proposed symposium on Drug Regulatory Systems, and the expansion of joint training and audits. Speaking on the occasion, Dr Raghuvanshi highlighted that states will be divided into two categories — manufacturing and primarily distribution — and will be ranked accordingly on the SHRESTH index. SHRESTH will have 27 indices for Manufacturing States across five key themes — human resources, infrastructure, licensing activities, surveillance activities and responsiveness — and 23 indices for primarily distribution states. States will submit the data on predefined metrics to CDSCO, which will be collected by the 25th day of every month, and these metrics will be scored on the first day of next month and shared with all states and Union Territories, Dr Raghuvanshi said. PTI PLB NSD NSD This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
Hans India
18 hours ago
- Hans India
Weight-loss drugs can lead to serious eye conditions
Drugs such as Ozempic, Wegovy, and Mounjaro (known as semaglutide and tirzepatide) have changed the way clinicians manage diabetes and obesity around the world. Collectively known as GLP-1 agonists, these drugs mimic the hormone GLP-1. This limits both hunger and interest in food, helping users lose weight, and helps control blood sugar levels. But two new studies show that people taking these drugs may have a small increased risk of serious eye conditions and vision loss. Here's what you need to know if you're taking or considering these medications. Non-arteritic anterior ischaemic optic neuropathy, or NAION, is a rare but devastating eye condition that occurs when blood flow to the optic nerve is suddenly reduced or blocked. It's also called an 'eye stroke'. The exact cause of NAION remains unclear, and there are no current treatments available. People with diabetes are at increased risk of developing NAION. Unlike other eye conditions that develop gradually, NAION causes a sudden, painless loss of vision. Patients typically notice the condition when they wake up and discover they've lost vision in one eye. Vision tends to worsen over a couple of weeks and slowly stabilises. Recovery of vision is variable, but around 70 per cent of people do not experience improvement in their vision. What has previous research shown? A previous study from 2024 found that participants prescribed semaglutide for diabetes were four times more likely to develop NAION. For those taking it for weight loss, the risk was almost eight times higher. In June, the European Medicines Agency concluded NAION represented a 'very rare' side effect of semaglutide medications: a one in 10,000 chance. However, recent studies suggest the risks may be lower than we first thought. In addition to NAION, there is also evidence to suggest GLP-1 drugs can worsen diabetic eye disease, also known as diabetic retinopathy. This occurs when high blood sugar levels damage the small blood vessels in the retina, which can lead to vision also show that patients with heart conditions who better adhere to their medication prescriptions have lower risks of NAION than those who don't. Doctors should discuss NAION risks during prescribing decisions and work with eye care providers to monitor regularly for diabetic eye disease. Patients need clear instructions to seek immediate medical attention for sudden vision loss and the need for regular eye examinations. Aggressive treatment of sleep apnoea and other heart conditions may also help reduce NAION risks. But for now, there remains an ongoing need for more research to understand how GLP-1 medications can affect the eye. (Flora Hui is with the University of Melbourne and Pete A Williams is from Karolinska Institutet)
